EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Waldenstrom macroglobulinemia with the combination of Fludarabine and cyclophosphamide Results in 21 patients



Treatment of Waldenstrom macroglobulinemia with the combination of Fludarabine and cyclophosphamide Results in 21 patients



Blood 102(11): 288b-289b, November 16



Fludarabine is effective in Waldenstrom macroglobulinemia with a response rate of 30% in previously treated patients. The combination of Fludarabine (FAMP) and cyclophosphamide (Cy) has been shown to be effective in chronic lymphoproliferative disorders such as chronic lymphocytic leukemia. Based on these data, we have administered the combination of fludarabine (25mg/m2 intravenously (IV) -D1-D3 days) and cyclophosphamide (300 mg/m2 IV -D1-D3) every 28 days to 21 pts. There were 14 males and 7 females. The median age was 63 yrs (36-82), hemoglobin level <100g/L in 33% of pts, albumin <40 g/L in 31% of pts, beta2 microglobulin >normal level in 73% of pts. 8 pts were previously untreated. The median of treatment in 13 previously treated pts was 1. FAMP CY was administered every 4 weeks for a median of 4 courses. Partial response was defined by at least 50% reduction of serum monoclonal protein and of tumor infiltrate at all involved sites. 15/21 (71%) pts were in partial response, 4 had stable disease (SD) and 2 had a progressive disease (PD). With a median of follow-up of 7 months (1.5-25.3), one patient relapsed at 19 mths. Two pts received an autologous hematopoietic stem cell transplantation (HSCT) (one in RP, one in SD) at 6 months. One pt received an a genotypic identical allogeneic HSCT in PR at 7 months. Two pts died: one from sepsis with a PD at 3 months after treatment discontinuation, and one in PR from acute myeloid leukemia at 6 months. Neutropenia grade 3-4 or/and thrombocytopenia grade 3-4 were observed in 7 cycles. Other toxicity was a pneumocystis pneumonia. In conclusion, the combination FAMP/Cy led to a high response rate, even in previously treated patients. However several published data have shown that stem cell collection could be unsuccessful after fludarabine-containing regimen The two pts who received autologous HCST had a HSCT graft collected before starting FMP+CY regimen. The use of stem-cell damaging agents has to be reconsidered in a therapeutic strategy including high-dose therapy and autologous HSCT.

(PDF 0-2 workdays service: $29.90)

Accession: 035980645

Download citation: RISBibTeXText



Related references

Rituximab and fludarabine or cyclophosphamide combination treatment for older waldenström macroglobulinemia patients. Turkish Journal of Haematology 30(4): 422-423, 2014

Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leukemia & Lymphoma 44(6): 993-996, 2003

Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia (Basingstoke) 19(10): 1831-1834, 2005

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98(9): 2640-2644, November 1, 2001

Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. American Journal of Hematology 91(8): 782-786, 2016

Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia. Clinical Lymphoma & Myeloma 6(2): 136-139, 2005

Clinical analysis of dexamethasone and rituximab in combination with cyclophosphamide in the treatment of 18 patients with Waldenström macroglobulinemia. Zhonghua Xue Ye Xue Za Zhi 39(7): 589-592, 2018

Fludarabine, cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia: An effective regimen requiring a new category of response criteria and a delayed assessment of results. Blood 110(11, Part 1): 388A, 2007

Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination. Leukemia & Lymphoma 51(12): 2288-2290, 2011

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 118(2): 434-443, 2012

Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia 13(2): 231-234, 2013

Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia. Leukemia & Lymphoma 49(6): 1209-1211, 2008

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Leukemia & Lymphoma: 1-3, 2016

Fludarabine-based combination therapies for Waldenström's macroglobulinemia. Clinical Lymphoma & Myeloma 9(1): 67-70, 2009

Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leukemia & Lymphoma 51(12): 2188-2197, 2011